Skip to main content
Clinical Trials/NCT00965419
NCT00965419TerminatedPhase 2

Long-Term, Open-Label, Safety Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder

Eli Lilly and Company1 site in 1 country267 target enrollmentStarted: September 2009Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Terminated
Enrollment
267
Locations
1
Primary Endpoint
Percentage of Participants With At Least One Serious Adverse Events (SAE) Over the Duration of the Study

Study Overview

Brief Summary

The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
6 Years to 18 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Edivoxetine

Experimental

All enrolled participants were administered starting dose of 0.1 milligram per kilogram per day (mg/kg/day), or participant specific known stable dose, rollover participants (LNBJ [No NCT number]) and (LNBF [NCT00922636]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.

Intervention: Edivoxetine (Drug)

Outcomes

Primary Outcomes

Percentage of Participants With At Least One Serious Adverse Events (SAE) Over the Duration of the Study

Time Frame: Baseline Through Week 252

Percentage of Participants experienced at least one SAE during the study. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.

Number of Participants With At Least One SAE

Time Frame: Baseline Through Week 252

Number of Participants experienced at least one SAE during the study. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.

Secondary Outcomes

  • Mean Change From Baseline Z-scores for Height(Baseline, Week 60; Baseline, Week 240)
  • Number of Participants Who Discontinued Due to Any Reason(Baseline Through Week 252)
  • Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)(Baseline Through Week 252)
  • Number of Participants With At Least One TEAE(Baseline Through Week 252)
  • Percentage of Participants With Discontinuation Due to Adverse Events (DCAEs)(Baseline Through Week 252)
  • Number of Participants With At Least One DCAEs(Baseline Through Week 252)
  • Percentage of Participants Who Discontinued Due to Any Reason(Baseline Through Week 252)
  • Percentage of Participants With Columbia-Suicide Severity Rating Scale (CSSRS) for Each Category(Baseline Through Week 252, Baseline, 1-month (mo) Follow-Up (f/u))
  • Mean Change From Baseline Z-Score for Weight(Baseline, Week 60; Baseline, Week 240)
  • Mean Change From Baseline Z-Score in Body Mass Index (BMI)(Baseline, Week 60; Baseline, Week 240)
  • Number of Participants With a Response Rate(Week 12)
  • Survival Curve Time to Response(Week 12)
  • Percentage of Participants in Sexual Maturation on Tanners Scale(Baseline Up to Week 252)
  • Number of Participants in Sexual Maturation on Tanners Scale(Baseline Up to Week 252)
  • Percentage of Participants With Response Rates(Week 12)
  • Mean Change From Baseline of Total Score SNAP-IV Oppositional Defiant Disorder (ODD) Subscale(Baseline, Week 12)
  • Percentage of Participants With Tobacco, Alcohol and Marijuana Use(Week 60 through Week 252)
  • Number of Participants With Tobacco, Alcohol and Marijuana Use(Week 60 through Week 252)
  • Mean Change From Baseline of Each Score Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) (Hyperactive/Impulsive, Inattentive and Total Score)(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Total Score Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Severity (CGI-ADHD-S)(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change of Total Score Teacher-rated Swanson Nolan, and Pelham Rating Scale-Revised (SNAP-IV) ADHD Subscales (Hyperactive/Impulsive, Inattentive and Total Score)(Baseline, Week 12)
  • Mean Change From Baseline of Each Total Score Conners Comprehensive Behavior Rating Scales (CP-CBRS) Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Text Revision (DSM-IV-TR) for Symptom Subscales Manic Episode and Mixed Episode(Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Each Total Score CP-CBRS (DSM-IV-TR) ADHD Symptom Subscales (Hyperactive/Impulsive and Inattentive)(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Each Total Score CP-CBRS DSM-IV-TR for Oppositional Defiant Disorder (ODD), Anxiety, Conduct Disorder and Major Depressive Episode(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Each Raw Score CP-CBRS Impairment Items Subscales for Schoolwork/Grades, Friendship/Relationships, and Home Life(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Each Total Score CP-CBRS Content Subscale for Aggressive Behaviors, Academic Difficulties, Social Problems, and Violence Potential)(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of the 5 Domain Scores Child Health and Illness Profile-Adolescent Edition (CHIP-AE) in 5 Health Outcome Domains (Satisfaction, Comfort, Resilience, Risk Avoidance and Achievement)(Baseline, Week 12; Baseline, Week 60; Baseline, Week 156)
  • Mean Change From Baseline of the 5 Domain Scores Child Health and Illness Profile-Child Edition (CHIP-CE) in 5 Health Outcome Domains (Satisfaction, Comfort, Resilience, Risk Avoidance and Achievement)(Baseline, Week 12; Baseline, Week 60; Baseline, Week 156)
  • Mean Change From Baseline of Total Score Euro-Qol Questionnaire - 5 Dimensions 3 Levels (EQ-5D-3L) Health State for Parent(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Total Score EQ-5D-3L Visual Analog Scale (VAS) for Parent(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change of From Baseline Total Score EQ-5D-3L Health State for Child(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change of From Baseline Total Score EQ-5D-3L VAS for Child(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Total Score EQ-5D-3L Health State for Adolescent(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Total Score EQ-5D-3L VAS(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Total Score Woodcock Johnson III Test of Achievement ([WJ III ACH])(Baseline, Week 60)
  • Mean Change From Baseline of Total Score Wide Range Achievement Test (WRAT 4)(Baseline, Week 60)
  • Mean Change From Baseline of Total Score Wechsler Intelligence Scale for Children Fourth Edition (WISC-IV)(Baseline, Week 60)
  • Mean Change From Baseline of Total Score Wechsler Adult Intelligence Scale - Third Edition (WAIS-III)(Baseline, Week 60)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials